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Background-—Identifying the best markers to judge the adequacy of lipid-lowering treatment is increasingly important for coronary
heart disease (CHD) prevention given that several novel, potent lipid-lowering therapies are in development. Reductions in LDL-C,
non-HDL-C, or apoB can all be used but which most closely relates to beneﬁt, as deﬁned by the reduction in events on statin
treatment, is not established.
Methods and Results-—We performed a random-effects frequentist and Bayesian meta-analysis of 7 placebo-controlled statin
trials in which LDL-C, non-HDL-C, and apoB values were available at baseline and at 1-year follow-up. Summary level data for
change in LDL-C, non-HDL-C, and apoB were related to the relative risk reduction from statin therapy in each trial. In frequentist
meta-analyses, the mean CHD risk reduction (95% CI) per standard deviation decrease in each marker across these 7 trials were
20.1% (15.6%, 24.3%) for LDL-C; 20.0% (15.2%, 24.7%) for non-HDL-C; and 24.4% (19.2%, 29.2%) for apoB. Compared within each
trial, risk reduction per change in apoB averaged 21.6% (12.0%, 31.2%) greater than changes in LDL-C (P<0.001) and 24.3% (22.4%,
26.2%) greater than changes in non-HDL-C (P<0.001). Similarly, in Bayesian meta-analyses using various prior distributions, Bayes
factors (BFs) favored reduction in apoB as more closely related to risk reduction from statins compared with LDL-C or non-HDL-C
(BFs ranging from 484 to 2380).
Conclusions-—Using both a frequentist and Bayesian approach, relative risk reduction across 7 major placebo-controlled statin
trials was more closely related to reductions in apoB than to reductions in either non-HDL-C or LDL-C. (J Am Heart Assoc. 2014;3:
e000759 doi: 10.1161/JAHA.113.000759)
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I
dentifying the best marker to judge the adequacy of
lipid-lowering treatment for coronary heart disease prevention
is increasingly important given that several novel potent lipid-
lowering therapies are being developed. Although recent guide-
lines
1–3 differ as to the importance of targets, all emphasize the
importance of LDL lowering with statins to prevent cardiovas-
cular events. The European and Canadian guidelines relate the
intensity of statin therapy to the decrease in LDL obtained with
statins whereas the American Heart Association/American
College of Cardiology Guidelines emphasize the statin regimens
used in the clinical trials. Moreover, even guidelines that
recommend statin targets do not clearly state on what evidence
their choice of target is determined. Thus, changes in LDL-C, non-
HDL-C, or apolipoprotein B (apoB) could all be used to assess the
response to statin therapy but which most closely relates to
risk reduction on statin treatment, has not been established.
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ORIGINAL RESEARCHAlthough, Boekholdt et al reported that non-HDL-C was
marginally superior to LDL-C and apoB as a marker of future
events on treatment,
4 the differences were clinically not
signiﬁcant. Similarly, in the Heart Protection study, all 3
equally predicted the risk of future events on treatment.
5
However, given that the on-treatment level of LDL is low in
most of these patients
6–8 and that event rates are also low,
accurately determining the relative precision of these highly
correlated markers for future events is challenging.
An alternative, more direct, and therefore potentially more
informative approach is to evaluate the relation between the
reduction in these markers and the observed beneﬁt
produced by statin therapy. The marker whose reduction
relates most directly to beneﬁt should also be the marker that
is best to identify those whose outcome might be improved by
further lipid lowering. Although change in apoB was more
closely associated with beneﬁt among statin trials in a recent
study, the differences between markers using a Bayesian
approach were modest due to methodological limitations.
9
Accordingly, we conducted both a frequentist and a
Bayesian meta-analysis of the relations of the statin-induced
changes in LDL-C, non-HDL-C, and apoB to the clinical beneﬁt,
as deﬁned by the reduction in risk, observed in the 7 placebo
controlled statin trials.
5,10–15
Methods
Data Sources
We searched the literature using PubMed from inception to
January 1, 2013 to identify all placebo-controlled RCTs of
statin therapy using the following search strategy adapted
from Boekholdt et al
4: hydroxymethylglutaryl coenzyme-A
reductase inhibitor, statin, atorvastatin, ﬂuvastatin, lovastatin,
simvastatin, pravastatin, rosuvastatin, apolipoprotein, choles-
terol, coronary heart disease, and cardiovascular disease. We
included only trials that reported 1-year changes from
baseline in LDL-C, non-HDL-C, and apoB during statin therapy.
We also excluded trials with a short duration (<2 years) of
follow-up or with fewer than 1000 participants enrolled. Two
authors (G.T. and K.W.) screened and abstracted reported
baseline and 1-year levels of cholesterol and apolipoprotein
values (or change at 1 year, if reported) as well as reported
relative risk reductions for all cardiovascular endpoints. Any
discordance in abstracted data was resolved by consensus
(G.T., K.W., A.D.S.). Amongst the statin trials, we excluded
those such as Post-CABG
16 in which multiple drugs were
allowed to reach the target that had been selected. We also
excluded statin trials that compared doses of statins, because
the greatest beneﬁt and the greatest reductions occur with
the initial dose. The between-group differences both of
change in markers and relative risk reduction will be much
smaller and therefore less reliable than those observed in the
statin vs placebo-design trials. For each included trial, we
selected the most comprehensive published coronary heart
disease (CHD) composite outcome for the meta-analysis. The
composite coronary heart disease (CHD) outcome selected
from each trial’s report included myocardial infarction and
coronary death. 4S,
10 CARDS,
14 and SPARCL
15 also included
resuscitated cardiac arrest. In AFCAPS/TexCAPS,
12 JUPI-
TER,
13 CARDS,
14 and SPARCL
15 unstable angina was also
included whereas in JUPITER,
13 CARDS,
15 and SPARCL
14
revascularization was included in the CHD outcome. We
selected CHD rather than total cardiovascular disease (CVD)
outcomes because ischemic and hemorrhagic strokes were
not always adequately differentiated and LDL is more closely
related to the pathophysiology of ischemic strokes as
opposed to hemorrhagic strokes. To calculate the reductions
in lipid markers on statin therapy, we calculated the difference
in lipid markers from baseline to 1 year in the treatment arm
and corrected this difference for the difference in the lipid
markers at baseline to 1 year in the control arm to limit
regression-dilution bias.
Statistical Analyses
The objective of this study was to relate changes in the plasma
levels of the 3 markers by statins to the relative risk reduction
observedwithstatintherapyfromclinicaltrials.Tocalculatethe
riskreduction(and95%CI)fromstatinsperchangeineachlipid
marker within each trial, we divided the logarithm of overall
treatment HR (95% CI) in each trial by the difference between
treatmentandcontrolgroupmarkerlevelsinSDsfromthattrial.
For comparability, the standard deviations reported by Boek-
holdt
4 (32 mg/dL for LDL-C, 36 mg/dL for non-HDL-C, and
27 mg/dL for apoB) were used in each calculation. Standard
errors for each point estimate were calculated from the
conﬁdence intervals. The results are presented as relative risk
reduction per SD decrease in the marker (ie, 1  HR).
Calculation of Variance
In clinical trials, the before- and after-treatment values from
which the changes in markers are estimated are derived from
the same individuals. Thus, the differences we modeled were
between paired samples. Moreover, LDL-C, non-HDL-C, and
apoB are all highly intercorrelated because they are
metabolically tied to each other. Accordingly, their changes
with therapy are not entirely independent of each other and
the degree of linkage is expressed by the correlation
coefﬁcient, which we used in calculating the statistical
signiﬁcance of differences between marker changes versus
beneﬁt. Without individual level data, we estimated the
standard errors for within-trial “head-to-head” differences
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Husing the standard formula for differences between log HRs
matched by trial.
17 In the absence of correlation coefﬁcients
reported in the selected trials to compute standard errors, we
used correlation coefﬁcients calculated from NHANES 2005-
2010
18 representative of adult residents of the United States:
0.94 for LDL-C versus non-HDL-C, 0.93 for non-HDL-C versus
apoB, and 0.89 for LDL-C versus apoB. Power to detect
smaller differences in means pre- and post-treatment will be
greater in paired versus unpaired analyses when there is
positive correlation among the samples.
Frequentist Meta-Analysis
Frequentist meta-analyses were performed as recommended
by Borenstein et al
17 using Comprehensive Meta-Analysis
software (Biostat) assuming arandomeffects model. We chose
random effects rather than a ﬁxed-effect model given the
differences in study design and statin studied. We performed 6
frequentist meta-analyses including 1 for each marker’sH R
calculation (per SD decrement) and 1 “head-to-head” compar-
isonofwithintrialdifferencesbetweeneachcombinationoflog
HRs. Point estimates of the beneﬁts associated with decre-
mentswerecalculatedbyexponentiationofthetrialHRbyeach
marker’s decrement in standard deviations. Heterogeneity was
assessed bytheQstatistic.Thepotential forselection biaswas
assessed by examining funnel plots with imputed studies and
Orwin’s fail-safe N statistics, which determines the number of
additional studies with a mean effect of 0 (ie, HR=1.0 or 0%
difference in HRs), which would be required to bring the overall
mean point estimate below a level we preselected as not
clinicallymeaningful(HR<1.09oradifferencebetweenanypair
of HRs, of less than 2%).
We repeated the key apoB versus non-HDL-C “head-to-
head” comparison removing each trial 1 at a time to provide
evidence to assess whether the inclusion of any 1 trial drove
the overall results. We also conducted a subgroup analysis for
this comparison whenever 2 groups with different attributes
were identiﬁed with more than 1 trial in each group.
Bayesian Meta-Analysis
We performed 3 different Bayesian meta-analyses, 1 for each
of the within-trial differences in log HRs for each 2-marker
combination. For each analysis we developed stochastic
results from Markov chain Monte Carlo (MCMC) simulation
with 5000 burn-ins and 50 000 generated posterior deviates
based on a non-informative prior distribution for the differ-
ence in log HRs and 3 different priors for the correlation
between log HRs ranging from non-informative to 1 reﬂecting
published marker correlations. Conclusions in the results are
based on the Bayes factor concept, which is the ratio of the
posterior odds of the hypotheses A against B to the prior odds
of hypotheses A against B. In our analyses the prior odds=1.0
assuming the HRs are equal and the posterior odds=the
estimated probability that newer marker’sH R> the older
marker’s divided by the probability that the older marker’sH R
> the newer marker’s. The larger the Bayes factor is, the
stronger evidence is towards hypothesis A with 1<BF<3
providing slight (“barely worth mentioning”) support for
hypothesis A, 3<BF<15 providing substantial support,
9 and
BF>15 providing, in our view, deﬁnitive support. Conversely
larger values of the reciprocal of the BF provide stronger
evidence towards hypothesis B.
We also replicated the Bayesian analyses published by
Robinson
9 and colleagues using their data and their model,
which included intercept, marker change, and trial duration
terms. For comparison we applied their approach to their data
using our model, which included only a marker change term
assuming intercept=0 (no reduction in risk if LDL is not
lowered) and no association with duration (ie, proportional
hazards over time). We compared these models in all 24 trials
with CHD events, in the 12 statin trials, which included 5 with
control groups receiving less intensive treatment, and in the
7 placebo-controlled statin trials.
Results
Trial Statistics Used in the Meta-Analysis
The 7 clinical trials described in Table 1 represent all
published, placebo-controlled studies, which have reported
baseline and on-treatment levels of LDL- C, non-HDL-C, and
apoB.
5,10–15 The results of each trial in terms of HRs
indicating the various reductions in risk of major coronary
events and in terms of the reductions achieved in LDL marker
levels are also shown in Table 1.
Frequentist Analysis of Risk Reduction Per SD
Change in Each Marker
The forest plots of the beneﬁts (95% CIs) per SD decrement
from these studies for each of the 3 indices—LDL-C, non-
HDL-C, and apoB— are shown in Figure 1 (additional details
are displayed in Figures S1 through S3). The mean relative
risk reductions per SD change in lipid marker (95% CI) among
these 7 trials were 20.1% (15.6%, 24.3%) for LDL-C; 20.0%
(15.2%, 24.7%) for non-HDL-C; and 24.4% (19.2%, 29.2%) for
apoB. Each of the individual risk reductions was signiﬁcantly
(P<0.05) greater than 0%. The “head-to-head” comparisons
are shown in more detail in Figures S4 through S6.1 and S6.4.
The overall within-trial difference between the reduction in
non-HDL-C and LDL-C with respect to risk reduction did not
differ signiﬁcantly from zero (2.4% [3.6%, 8.4%] favoring
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HLDL-C, P=0.445). However, the risk reduction from statins per
reductions in apoB averaged 21.6% (12.0%, 31.2%) greater
than reductions in LDL-C (P<0.001) and 24.3% (22.4%, 26.2%)
greater than reduction in non-HDL-C (P<0.001).
The apoB versus non-HDL-C comparison was not substan-
tially altered with respect to statistical signiﬁcance or
magnitude of the effect size estimate by the exclusion of
any 1 trial (Figure S6.2). In addition, although the funnel plot
(Figure S6.3) showed some asymmetry indicative of potential
selection bias, the inclusion of 2 trials imputed to make the
funnel plot symmetric did not materially affect the ﬁndings.
Frequentist Meta-Analysis Statistics
As shown in Table 2, heterogeneity was not statistically
signiﬁcant across all the frequentist meta-analyses (each Q
Table 1. Study Characteristics Included in the Risk Associations Considered in Meta-Analysis
Trial
Year
Published
Baseline
CVD (%) CHD Events* HR (95% CI)
1-Year on Trial Levels (mg/dL)
Control Group Treatment Group Difference (SDs
†)
LDLC
Non
HDLC apoB LDLC
Non
HDLC apoB LDLC
Non
HDLC apoB
4S 1998 100 0.66 (0.59, 0.75) 190 216 117 118 140 81 2.25 2.11 1.33
LIPID 1998 100 0.76 (0.68, 0.85) 150 181 134 108 136 104 1.31 1.25 1.11
AF/TexCAPS 1998 0 0.63 (0.50, 0.79) 156 190 123 115 144 96 1.28 1.28 1.00
JUPITER 2008 0 0.56 (0.46, 0.69) 109 137 105 62 84 71 1.47 1.47 1.26
SPARCL 2006 100 0.80 (0.69, 0.92) 132 160 130 70 92 81 1.94 1.89 1.81
CARDS 2004 0 0.63 (0.48, 0.83) 120 158 111 72 100 80 1.50 1.60 1.15
HPS 2002/12 65 0.76 (0.72, 0.81) 124 178 120 74 113 84 1.57 1.80 1.33
CVD indicates cardiovascular disease; HPS, heart protection study; HDL-C, high-density lipoprotein cholesterol; LDLC, low-density lipoprotein cholesterol.
*The composite coronary heart disease (CHD) outcome selected from each trial’s report included myocardial infarction and coronary death. 4S, CARDS, and SPARCL included resuscitated
cardiac arrest. AF/TexCAPS, CARDS, SPARCL, and JUPITER included unstable angina. CARDS, SPARCL, and JUPITER included revascularization.
†The difference between the treatment and control groups’ means divided by the standard deviations reported by Boekholdt et al
4 (32 mg/dL for LDL-C, 36 mg/dL for non-HDL-C, and
27 mg/dL for apoB).
Figure 1. Random effects meta-analysis results with marker
sizes proportional to the precision of each estimate for the
estimated reduction in risk per 1-SD decrease of each marker.
Overall LDL-C (red): 20.1% (15.6%, 24.3%); Non-HDL-C (black):
20.0% (15.2%, 24.7%); ApoB (blue): 24.4% (19.2%, 29.2%).
Summary of within trial “head-to-head” comparisons: LDL-C was
2.4% (3.6%, 8.4%) > non-HDL-C (P=0.445); apoB was 21.6%
(12.0%, 31.2%) > than LDL-C (P<0.001) and 24.3% (22.4%, 26.2%)
> non-HDL-C (P<0.001). LDL-C indicates low-density lipoprotein
cholesterol; HDL-C, high-density lipoprotein cholesterol.
Table 2. Selected Statistics From Each Meta-Analysis
Marker(s) Q* P Value I
2 Fail safe N
†
LDL-C 9.5 0.147 37.0 9
Non-HDL-C 9.5 0.147 37.0 9
ApoB 8.7 0.190 31.2 13
Non-HDL-C—LDL-C 7.3 0.292 18.1 0
‡
ApoB—LDL-C 5.4 0.497 0.0 11
ApoB—non-HDL-C 8.6 0.197 30.3 15
HDL-C indicates high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein
cholesterol.
*Higher Q statistic values indicate greater heterogeneity.
†The number of trials with mean effect of 0 (ie, HR=1.0 or a 0% HR difference) which
would have to be added in addition to the 7 trials observed to bring the overall HR within
1.09% or a log HR difference within 1.8% which would be trivial in our judgment.
‡Fail safe N not calculated since the difference is already trivial.
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Hstatistic P>0.14) perhaps as a result of the relatively small
numberoftrialsincluded.Ontheotherhand,withtheexception
of the comparison of the 2 cholesterol markers, the I
2 statistic
ranged in the low or near the low to moderate range of 25% to
50%,
17thus indicatingsome of thevariance in thetrials’ results
maybeattributabletorealinﬂuencesofdifferencesinthetrials’
attributes. However, we estimate that at least 9 trials with no
association would have to be added to the 7 included trials
included to reduce the overall results to nonsigniﬁcance or to a
magnitudedeemednotclinicallymeaningful(ie,aHR≤1.09ora
difference≤2%) (Table 2). Taken altogether these statistics
indicate that our ﬁndings of a difference between the relative
risk reductions per SD decrement of apoB versus each
cholesterol marker are robust.
Bayesian Meta-Analysis
The Bayesian analysis is presented in detail in the appendix
pages 11 to 21. If a noninformative prior for the correlation
between log apoB HR and log non-HDL-C HR is assumed, the
Bayes factor favoring log apoB HR over log non-HDL-C HR is
484 (Table S4). A similarly deﬁnitive Bayes factor (BF=1110)
favoring apoB over non-HDL-C results from using a uniform
prior distribution of correlation between 0.5 and 1.0 (Table
S3). If the prior distribution is based on the published
19–23
correlations (truncated normal with mean=0.87, and vari-
ance=0.17
2), the Bayes factor favoring log apoB HR over log
non-HDL-C is 2380 (Table S2). With an informative prior
distribution for the correlation between apoB and LDL-C
(truncated normal with mean=0.84, and variance=0.11
2)
yields BF=188 favoring apoB. Similarly, an informative prior
distribution for the correlation between non-HDL-C and LDL-C
(r=0.89, SD=0.06) yields a BF of 6.21 favoring LDL-C,
indicating there is no important advantage of non-HDL-C
over LDL-C in these data. The principal results of the Bayesian
analysis are, therefore, consistent with the frequentist
analysis.
Our replication of the Bayesian meta-analyses conducted
by Robinson et al
9 presented in Figure S8 (and described
on pages 19 to 21 of the appendix), indicated that the
differences between their ﬁndings and ours are principally
attributable to differences in analytical methods.
Implications for Assessing the Adequacy of the
Response to Therapy
To illustrate how the choice of a marker could inﬂuence the
assessment of the response to therapy and the potential
beneﬁts of uptitration of statin therapy based on various lipid
markers, we examined lipid values from the NHANES 2005–
2010 survey. The corresponding population values of non-
HDL-C and apoB that are equivalent to the percentile values of
an LDL-C of 70 mg/dL would be 90 mg/dL, and 65 mg/dL,
respectively. To estimate the additional beneﬁts that might
accrue if LDL-lowering therapy were based on either non-HDL-
C or apoB rather than LDL-C, the decrease in events that
would be predicted to occur with reductions of LDL-C, non-
HDL-C, and apoB to these equivalent levels were calculated
for 3 treatment scenarios. The results are presented in
Table 3 and are based on different baseline marker levels
representing: (1) the mean of the achieved marker levels
across the 7 trials; (2) a 1-standard deviation above the mean
achieved; and (3) a 2-standard deviation above the mean
achieved. As listed in each scenario, the relative percent
Table 3. Illustrative Calculations Using Parameter Estimates From the Present Analysis
Scenario From Marker
Marker Level
(mg/dL)
Decrement
Risk%
Reduction %>LDL-C mg/dL % SDs
Mean LDL-C 88 18 20% 0.56 12%
Non-HDL-C 116 26 22% 0.72 15% 26%
apoB 85 20 24% 0.74 19% 58%
Mean+1 SD LDL-C 120 50 42% 1.56 30%*
Non-HDL-C 152 62 41% 1.72 32% 8%
apoB 112 47 42% 1.74 39%* 30%
Mean+2 SD LDL-C 152 82 54% 2.56 44%
Non-HDL-C 188 98 52% 2.72 46% 4%
apoB 139 74 53% 2.74 54% 22%
Each scenario involves reduction to the NHANES 2005-2010 8th percentile of each marker: 70 mg/dL of LDL-C, 90 mg/dL of non-HDL-C, and 65 mg/dL of apoB. Mean levels are the
simple average treatment group on treatment levels across the 7 placebo-controlled trials. Risk reductions are estimated from the point estimate of each marker’s overall HR per SD from
Figure 1: 0.799 per 32 mg/dL of LDL-C, 0.800 per 36 mg/dL of non-HDL-C, and 0.756 per 27 mg/dL of apoB. HDL-C indicates high-density lipoprotein cholesterol; LDL-C, low-density
lipoprotein cholesterol.
*Illustrated in Figure 2.
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expected, the risk reduction would differ with the greatest
beneﬁt achieved at the highest baseline levels (Figure 2).
More importantly, in each scenario, beneﬁt would be
substantially greater if therapy were targeted at apoB rather
than at LDL-C or non-HDL-C.
Discussion
Using both a frequentist and Bayesian approach, we demon-
strate that relative risk reduction from statin therapy in the 7
major placebo-controlled statin trials was more closely related
to reductions in apoB than to reductions in either non-HDL-C
or LDL-C. Our results point to a hierarchy of accuracy
amongst the 3 markers with reductions in apoB being
associated with the greatest risk reduction from statin
therapy whereas changes in non-HDL-C and LDL-C appeared
to be statistically indistinguishable with respect to risk
reduction of statin therapy. These ﬁndings should be expected
given that statins lower LDL-C and non-HDL-C more than they
lower apoB.
24 Accordingly, these results indicate that reduc-
tions in apoB are more closely related to beneﬁt from statin
therapy than are changes in the cholesterol markers and
support apoB as the most informative marker of the adequacy
of statin therapy. These ﬁndings also extend our prior meta-
analysis demonstrating that apoB was superior to LDL-C or
non-HDL-C in predicting cardiovascular events.
25
By contrast, Boekholdt et al
4 and Parish et al
5 did not
identify any superiority for apoB as a marker of residual risk in
patients whose LDL had been substantially reduced by statin
therapy. However, these ﬁndings do not conﬂict with ours
since the issue of residual risk is different from the issue of
beneﬁt. The absolute level of LDL determines the absolute
residual risk related to LDL, which, in most of the patients in
these studies, was low following statin therapy. At the same
time, there are multiple other determinants of cardiovascular
events while on statin therapy such as extent of coronary
artery disease, left ventricular function, renal function, blood
pressure, HDL, diabetes, smoking, and age. Moreover, it is
certainly possible that once arterial damage is sufﬁciently
advanced the processes of inﬂammation and partial repair will
continue to produce non-LDL-related events and these
mechanisms might account for the majority of events in
patients on statin therapy.
Robinson and colleagues
9 have previously compared the
relations of the 3 markers, LDL-C, non-HDL-C, and apoB, to
risk reduction from statin therapy using a Bayesian meta-
analysis. While their primary comparison was based on
multiple therapies, a number of which were unsuccessful
in reducing LDL or clinical events, they also found that change
in apoB was more closely related to the risk reduction in
statin trials than changes in non-HDL-C or LDL-C. However,
the magnitude of their ﬁndings in favor of apoB was much less
than in the present analysis. The differences between their
results and ours appear to be due to differences in analytic
methods. Robinson et al
9 evaluated the 3 markers based on
how well changes induced by medications ﬁt a 3-parameter
simple linear model and did not focus primarily on the slope,
which directly expresses the degree of change. Moreover, our
Bayes factors were calculated accounting for the fact that the
markers are highly intercorrelated and the changes induced
by statins occur in the same individuals.
The HPS
6 and the CTT meta-analysis
7 demonstrated that a
reduction in LDL-C of 1 mmol/L was associated with a 20%
reduction in clinical events. Indeed, the same character of
relationship between clinical events and change in LDL is
documented in this study expressed in different units.
Although not widely appreciated, this means that the total
risk reduction possible from statin therapy relates to the
absolute level of LDL – the higher the level of LDL, the more
units of decrease that are possible, and therefore, the greater
012
LDL-C 70 88 120 152
Non-HDL-C 90 116 152 188
ApoB 65 85 112 139
level (mg/dl)
Figure 2. Illustration of the implications of the ﬁnding of
statistically signiﬁcant difference in different markers’ hazard
ratios per standard deviation decrements. The population
represented by the gray bell-shaped curve includes subjects
eligible for, and treated under, the 7 placebo-controlled statin
trials. The curves represent the hazard ratios (HRs) relative to
2 standard deviations (SDs) below the mean of this population
using the point estimate for each marker’s HR per SD (0.799
for LDL-C, 0.800 for non-HDL-C, and 0.756 for apoB). The
sample calculations use these parameters to estimate risk
reductions if individuals with marker levels 1 SD above the
mean are reduced to the 8th NHANES 2005–2010 percentile
level: 70 mg/dL for LDL-C, 65 mg/dL for apoB, and 90 mg/
dL for non-HDL-C. A, 50 mg/dL (42%) reduction in LDL-C from
120 to 70 mg/dL would be expected to reduce CHD risk by
30%. Similar decreases to equivalent target levels of non-HDL-
C and apoB would yield expected risk decreases of 32% and
39%, respectively. CHD indicates coronary heart disease; LDL-
C indicates low-density lipoprotein cholesterol; HDL-C, high-
density lipoprotein cholesterol
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5 mmol/L will beneﬁt with successive reductions in events
from 5 to 4 and 4 to 3 and 3 to 2 mmol/L LDL-C. In
accordance with the results of both the HPS and the CTT
meta-analysis, we demonstrate that the beneﬁt of statin
therapy is directly proportional to the baseline LDL.
All guidelines accept that the level of LDL is a major
determinant of the risk of vascular disease and that lowering
LDL is a potent intervention to reduce the risk of cardiovas-
cular disease. That said, the recent Canadian (1) and
European (2) guidelines remain focused on high baseline
LDL and use speciﬁc targets for LDL-C, non-HDL-C, and apoB
for lipid lowering whereas the recent American guidelines
(3) deemphasize the baseline LDL levels for statin initiation
and the validity of targets for LDL-lowering therapy. Although
the differences with respect to targets should not be
exaggerated since the actual recommendation of the AHA/
ACC guidelines regarding targets is null – that is, they neither
recommend for nor against targets – and they explicitly allow
follow-up testing to determine the adequacy of response. The
AHA/ACC guidelines are correct to point out that there is no
meaningful difference between, for example, an LDL-C of
2.1 mmol/L and an LDL-C of 2.0 mmol/L. Indeed, the
relationship we have noted predicts progressively less
absolute beneﬁt as levels of LDL are lowered. More impor-
tantly, the results are also in keeping with the recent meta-
analysis of residual risk by Boekholdt et al demonstrating a
relatively low level of residual risk based on any lipid marker in
individuals treated with statins.
The differences we have demonstrated are based on
differences in the mass of cholesterol present in apoB
particles, differences in the response of LDL-C, non-HDL-C,
and apoB to statin therapy and differences in the rate at which
different LDL particles are cleared by the LDL pathway. The
primary effect of statins is to reduce hepatic cholesterol
synthesis, which in turn, will increase uptake of LDL particles
by the liver. Because statins reduce LDL-C substantially more
than VLDL triglycerides, cholesterol ester transfer protein
mediated exchange of cholesterol ester and triglyceride
between LDL particles and VLDL particles will increase with
the net result that LDL particles become triglyceride-enriched
and cholesterol-ester depleted. The triglyceride then tends to
be hydrolyzed making the LDL particles smaller and denser.
Smaller and denser LDL particles bind less avidly to the LDL
receptor and therefore tend to be removed less effectively
from plasma. The overall result is that statins reduce LDL-C
substantially, non-HDL-C less, and apoB even less.
24
As we have illustrated, apoB may identify a subgroup of
subjects with cholesterol-depleted apoB particles that point to
an incomplete response to statin therapy. Thus, particularly in
subjects with on-treatment levels of apoB above the mean of
the clinical trials we have analyzed, a level that corresponds to
approximately the 40th percentile of the American population,
signiﬁcant additional beneﬁt appeared to be possible. Given
these results and given that the response to statin therapy is
variable,
26 we believe the suggestion by AHA/ACC that
the response to statin therapy be assessed is reasonable. On
the other hand, we acknowledge that until further research is
completed, the deﬁnition of an incomplete response within an
individual subject requires clinical judgment, which as we
have argued elsewhere,
27 is core to clinical care and well
within the options outlined by AHA/ACC guidelines.
This analysis has several limitations that deserve mention.
We included only statin trials since our comparison of the
markers is to beneﬁt (ie, risk reduction) and only this agent
has been consistently associated with beneﬁt. We did not
include the statin trials that compared different regimens (eg,
high vs low potency statins) since the results of these studies
are less clear with respect to beneﬁt attributed to each lipid
marker than placebo-controlled trials. We also related overall
statin beneﬁt to changes in cholesterol or apoB only over the
ﬁrst year of treatment when the largest change in cholesterol
and apoB are expected to occur. Our meta-analyses were
also limited to published reports and we did not have access
to individual-level data. However, our ﬁnding of no signiﬁcant
heterogeneity, our use of various prior distributions based on
independent estimates of the correlations and the agreement
between our frequentist and Bayesian analyses suggest that
our ﬁndings are highly consistent and robust. We also used
the correlations between lipid markers rather than the
correlation between change in markers for our analyses to
calculate the standard errors, which may have somewhat
slightly overestimated these correlations but would be
expected to have only trivial differences in the overall
results. Finally, the several included RCTs excluded severe
hypertriglyceridemia and therefore limited entry to partici-
pants with less extreme elevations in apoB, which may have
attenuated the association between changes in apoB and
beneﬁt.
Summary
In summary, using both frequentist and Bayesian approaches
we demonstrate that reduction in apoB is more closely
associated with the risk reduction produced by statin therapy
and that apoB-targeted statin therapy may produce signiﬁ-
cantly greater beneﬁt than therapy targeted to either LDL-C or
non-HDL-C.
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